Association of glycemia with distal peripheral neuropathy
| Exposure | Unadjusted | Model 1 | Model 2 | |||
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
| Time in range (70–180 mg/dL) (per 10% lower)* | 1.26 (1.04 to 1.53) | 0.021 | 1.25 (1.02 to 1.52) | 0.031 | 1.23 (0.99 to 1.52) | 0.060 |
| Time above range (>180 mg/dL) (per 10% higher)* | 1.24 (1.03 to 1.50) | 0.024 | 1.23 (1.02 to 1.50) | 0.035 | 1.22 (0.99 to 1.50) | 0.061 |
| % coefficient of variations (per 6% higher (1 SD)) | 1.25 (0.83 to 1.86) | 0.283 | 1.24 (0.82 to 1.88) | 0.312 | 1.19 (0.75 to 1.90) | 0.457 |
| GMI (per 1% higher) | 1.82 (1.08 to 3.07) | 0.024 | 1.79 (1.05 to 3.04) | 0.033 | 1.81 (1.02 to 3.20) | 0.042 |
| HbA1c (per 1% or 11 mmol/mol higher) | 1.29 (0.97 to 1.70) | 0.08 | 1.25 (0.93 to 1.69) | 0.139 | 1.29 (0.93 to 1.79) | 0.129 |
| Duration of diabetes (per 10 years longer) | 1.15 (0.77 to 1.71) | 0.51 | 1.19 (0.77 to 1.82) | 0.433 | 1.13 (0.73 to 1.75) | 0.575 |
Sixty-two of 105 participants with a total MNSI questionnaire score ≥2 were defined as having distal peripheral neuropathy in this analysis.
Model 1 is adjusted for age, gender, race. Model 2 additionally adjusts for BMI, eGFR, use of insulin and use of sulfonylureas. In model 2, all outcomes except duration of diabetes additionally adjust for duration of diabetes.
*10%=144 minutes/day.
BMI, body mass index; eGFR, estimated glomerular filtration rate; GMI, glucose management indicator; HbA1c, hemoglobin A1c; MNSI, Michigan Neuropathy Screening Instrument.